Elsevier

Clinical Immunology

Volume 131, Issue 3, June 2009, Pages 415-425
Clinical Immunology

Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions

https://doi.org/10.1016/j.clim.2009.02.001Get rights and content

Abstract

Plasma and cellular HCV RNA and core antigen were tested in monocyte-derived DC (MDDC) from chronic hepatitis C patients undergoing treatment with peg-interferon α2b/ribavirin. DC allostimulatory capacity, HCV-specific T-cell reactivity and IL-12 production were measured at baseline and treatment week (TW)12. Using DC and autologous CD4+T-cells, obtained at baseline and TW12, we performed cross-over experiments to determine the relative role of DC and/or T-cells for impaired immune reactivity to HCV. HCV RNA and HCV core plasma levels had an impact on DC phenotype and allostimulatory capacity. In contrast, HCV genome/core protein, although detectable in DC from some patients had no effect on DC function. Antiviral immunity at TW12 was not improved in patients who remained HCV RNA positive, while early viraemia clearance (TW12) improved antiviral responses. The cross-over experiment revealed that changes in DC, rather than CD4+T cells have a major role for enhanced anti-HCV responses.

Introduction

It is estimated that 170 million people worldwide are chronically infected with the hepatitis C virus (HCV), one of the principal causes of chronic hepatitis, cirrhosis and hepatocellular carcinoma [1], [2]. Some individuals are able to clear HCV spontaneously during acute HCV infection by mounting vigorous cellular immune responses directed to multiple HCV antigens [1], [3], [4], [5], [6]. However in the great majority of patients viraemia persists, associated with impaired HCV-specific T-cell reactivity [6], [7]. The mechanisms by which HCV establishes chronic infection are not fully understood.

Dendritic cells (DC), the most potent antigen presenting cells, have a critical role in the initiation of adaptive immune responses [8], [9], [10]. Consequently, DC functions are targeted by numerous viruses in order to disrupt the generation of efficient antiviral cellular immune responses [11], [12], [13], [14], [15], [16], [17]. In HCV infection, several studies, using monocyte-derived DC (MDDC), have suggested that dysfunctional DC are responsible for the impaired Th1 response [18], [19], [20], [21], [22], [23], [24]. However, other authors found no significant defects in the phenotype and function of MDDC generated from patients with chronic hepatitis C (CHC) [25], [26], [27], [28]. Similarly, controversial findings have been reported when using circulating myeloid or plasmacytoid dendritic cells, directly isolated from peripheral blood [27], [29], [30], [31], [32].

In the present study we investigated viraemia levels and MDDC functions and phenotype before treatment and early during antiviral therapy, trying to understand the role of DC in CHC. Our working hypothesis was that ‘early’ (by week 12 of treatment, TW12) clearance of viraemia and subsequent viral antigen loss leads to improvement of dendritic cell functions, promoting HCV-specific Th1 responses in the host. We further investigated whether improved adaptive immune response after ‘early’ viraemia clearance is due to restored DC function, or to improvement of CD4+ T-cell reactivity. In addition, we tested the relation between the presence of HCV genomic sequences and proteins (in particular HCV core) in patients' plasma and in DC lysates, and DC functions and phenotype.

Section snippets

Patients

Thirty-five consecutive (n = 35), treatment-naïve patients with chronic hepatitis C, monitored at the Hepatitis Clinic, University College Hospital, London, were enrolled in the study (Table 1) after giving informed consent. All patients were positive for anti-HCV and HCV RNA (Amplicor HCV v2.0; Roche Molecular Systems, Pleasanton, CA). The HCV genotype was determined by a restriction–fragment–length–polymorphism method [33]. All patients were tested negative for HBsAg and antibodies against

Results

MDDC from CHC patients and healthy controls were tested both as ‘immature’ DC and as ‘mature’ DC following stimulation with LPS. ‘Immature’ DC from healthy controls showed a trend for higher allostimulatory capacity than MDDC from CHC patients (P = 0.063) (data not shown).The difference between the two groups was significant when testing ‘mature’ DC from the same subjects (P = 0.015) (Fig. 1).

Using ultra-sensitive PCR methodology (RT-PCR NAH), the positive strand of HCV RNA was detected in MDDC

Discussion

The mechanisms that HCV uses to down-regulate antiviral immunity, thus promoting HCV persistence, are still not well defined. To gain a better understanding, we investigated the impact of MDDC phenotypic and functional changes in relation to early on-treatment viraemia clearance on CD4+ T-cell reactivity, extending previous findings that rapid viraemia clearance is associated with enhanced HCV-specific, T-cell responses [36]. We demonstrated that in patients who cleared the virus by TW12, the

Acknowledgment

This study was funded in part by a research grant from Schering-Plough, Welwyn Garden City, United Kingdom.

References (46)

  • K. Ishak et al.

    Histological grading and staging of chronic hepatitis

    J. Hepatol.

    (1995)
  • B. Rehermann et al.

    Immunological techniques in viral hepatitis

    J. Hepatol.

    (2007)
  • K.H. Tang et al.

    Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy

    J. Hepatol.

    (2005)
  • F. Lechner et al.

    Analysis of successful immune responses in persons infected with hepatitis C virus

    J. Exp. Med.

    (2000)
  • F. Lechner et al.

    CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained

    Eur. J. Immunol.

    (2000)
  • R. Thimme et al.

    Determinants of viral clearance and persistence during acute hepatitis C virus infection

    J. Exp. Med.

    (2001)
  • R. Thimme et al.

    Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

    Proc. Natl. Acad. Sci. U. S. A.

    (2002)
  • M.E. Cramp et al.

    Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia

    Gut

    (1999)
  • R.M. Steinman et al.

    Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice

    Proc. Natl. Acad. Sci. U. S. A

    (1978)
  • R.M. Steinman et al.

    Tolerogenic dendritic cells

    Annu. Rev. Immunol.

    (2003)
  • P. Guermonprez et al.

    Antigen presentation and T cell stimulation by dendritic cells

    Annu. Rev. Immunol.

    (2002)
  • J. Engelmayer et al.

    Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion

    J. Immunol.

    (1999)
  • I. Fugier-Vivier et al.

    Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells

    J. Exp. Med.

    (1997)
  • Cited by (14)

    View all citing articles on Scopus
    1

    Currently in the Department of Gastroenterology and Hepatology, 424 Army General Teaching Hospital of Thessaloniki.

    2

    Current address is Immunology and Infectious Diseases, Novartis Pharma AG, CH-4002 Basel, Switzerland.

    View full text